Spots Global Cancer Trial Database for Study to Evaluate CCS1477 in Haematological Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Evaluate CCS1477 in Haematological Malignancies
Official Title: An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
Study ID: NCT04068597
Study Description
Brief Summary: A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Detailed Description: This includes patients with Peripheral T-cell lymphoma.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic, Phoenix, Arizona, United States
Institute Bergonie, Bordeaux, , France
Institute Gustave Roussy, Villejuif, , France
University Hospital Vall D'Hebron, Barcelona, , Spain
CIOCC Hospital Universitario HM Sanchinarro, Madrid, , Spain
Karolinska Institute, Stockholm, , Sweden
The Royal Marsden, Sutton, Surrey, United Kingdom
University Hospital of Wales, Cardiff, , United Kingdom
Western General Hospital, Edinburgh, , United Kingdom
Gartnavel General Hospital, Glasgow, , United Kingdom
Leicester Royal Infirmary, Leicester, , United Kingdom
NIHR University College London Clinical Research Facility, London, , United Kingdom
The Christie Hospital, Manchester, , United Kingdom
Cancer and Haematology Centre, Oxford, , United Kingdom
University Hospital of Southampton, Southampton, , United Kingdom
Contact Details
Name: Tim Somervaille
Affiliation: The Christie NHS Foundation Trust
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
